行情

INFI

INFI

Infinity制药
NASDAQ

实时行情|Nasdaq Last Sale

0.8799
-0.0557
-5.95%
休市 16:00 03/27 EDT
开盘
0.8960
昨收
0.9356
最高
0.9000
最低
0.8355
成交量
10.14万
成交额
--
52周最高
1.930
52周最低
0.6000
市值
5,053.58万
市盈率(TTM)
-1.0655
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测INFI价格均价为2.875,最高价位3.500,最低价为1.500。

EPS

INFI 新闻

更多
  • 新加坡出台新规:公共场所不保持一米距离或将入狱
  • 澎湃新闻 · 3小时前
  • 安倍呼吁日本民众做好防疫持久战准备 暂不宣布进入紧急状态
  • 海外网 · 3小时前
  • 美股与美国经济,谁带崩了谁?
  • 证券市场红周刊 · 3小时前
  • 5G iPhone仍有望如期推出 供应商否认被告知延迟出货
  • TechWeb · 3小时前

所属板块

生物技术和医学研究
-2.43%
制药与医学研究
-0.87%

热门股票

代码
价格
涨跌幅

INFI 简况

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.
展开

微牛提供Infinity Pharmaceuticals Inc.(NASDAQ-INFI)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的INFI股票新闻,以帮助您做出投资决策。